KRAS and colorectal carcinoma: Among the stage II CRC patients, the 3-year DFS rate for both BRAF and KRAS mutation (+) patients was 25%, for BRAF mutation (–) and KRAS mutation (+) patients it was 76.3%, for BRAF mutation (+) and KRAS mutation (−) patients it was 83.1%, and for both BRAF and KRAS mutation (−) patients it wasc84.1% (p < 0.01, number of patients: 1, 28, 6, and 17, respectively).